Niraparib Slows Ovarian Cancer Progression.
Results from a phase III trial indicate that maintenance therapy with the PARP inhibitor niraparib is more effective than placebo in slowing the progression of recurrent platinum-sensitive ovarian cancer. Improved progression-free survival was seen regardless of the presence or absence of germline BRCA mutations, or of homologous recombination deficiency; however, patients who had these mutations or defective DNA repair did better.
D019313:BRCA1 Protein / Q000235:genetics; D024682:BRCA2 Protein / Q000235:genetics; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D005260:Female; D018095:Germ-Line Mutation; D006801:Humans; D007191:Indazoles / Q000627:therapeutic use*; D060046:Maintenance Chemotherapy; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics; D010880:Piperidines / Q000627:therapeutic use*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human; D007191:Indazoles; D010880:Piperidines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C545685:niraparib